Advertisement

Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora’s box

  • Mary-Ann FitzcharlesEmail author
  • Winfried Hauser
Pain in Rheumatology (W Nielson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pain in Rheumatology

Abstract

Purpose

Interest in cannabinoids as a therapy in rheumatic diseases has grown exponentially. With legalization of medical and recreational cannabis in many jurisdictions worldwide, patients have easier access and opportunity to explore medicinal use. We report on the evidence for effect of cannabinoids in rheumatic diseases and critically address the current challenges surrounding use.

Recent findings

Preclinical study of cannabinoids points to an effect on pain and inflammation, fundamental features of rheumatic diseases. The findings of the few randomized controlled trials (RCTSs) of cannabis-based medicines in rheumatic diseases are limited by short study duration, small study samples, and methodology flaws. There are no RCTs of medical cannabis in rheumatic diseases. Therefore, current guidelines mostly recommend against use of any cannabinoid product for rheumatology patients.

Summary

Even with limited clinical evidence, patients are increasingly showing interest in cannabis. Rheumatologists must be diligent in exploring other established treatment options prior to a trial of cannabinoids in any form. Cannabis holds potential as a treasure chest for rheumatic disease treatment, but with true effect and risks largely unknown and requiring study. Governments’ move to legalize medical cannabis has bypassed the established procedures of drug approval and opened Pandora’s box.

Keywords

Cannabinoids Rheumatic disease Medicinal herbal cannabis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Fitzcharles declares that she has no conflicts of interest.

Dr. Häuser received travel and hotel reimbursement from Bioevents. Dr. Häuser is the head of the task force of a position paper of the European Pain Federation on cannabis-based medicines and medical cannabis for chronic pain, and a member of the task force of the German Pain Society of a position paper on cannabis-based medicines and medical cannabis for chronic pain.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Altawil R, Saevarsdottir S, Wedren S, Alfredsson L, Klareskog L, Lampa J. Remaining pain in early rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res (Hoboken). 2016;68(8):1061–8.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Fitzcharles MA, Perrot S, Hauser W. Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain. 2018;22(9):1565–76.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Stoicea N, Costa A, Periel L, Uribe A, Weaver T, Bergese SD. Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review. Medicine (Baltimore). 2019;98(20):e15425.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019;365:l1141.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Therapeutics. Survey results on medical marijuana. Can Rheumatol Assoc J. 2017;27(4):27.Google Scholar
  6. 6.
    • Fitzcharles MA, Niaki OZ, Hauser W, Hazlewood G. Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases. J Rheumatol. 2019;46(5):532–8 A guidance document providing evidence for effects as well as risks and unknowns for rheumatologists caring for patients requesting information or using medical cannabis.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–48.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.•
    Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, et al. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018;8(1):14280 Explanation of the complexities of the Cannabis plant with examples of preclinical studies that may explain the entourage effects of the highly variable molecular content of the plant.Google Scholar
  10. 10.
    Taylor DR, Hall W. Respiratory health effects of cannabis: position statement of the Thoracic Society of Australia and New Zealand. Intern Med J. 2003;33(7):310–3.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    •• van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860–9 A valuable study that provides information about the pharmacokinetics and effects of inhaled cannabis in patients with fibromyalgiaPubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.••
    Health Canada. Information for health care professionals—cannabis and the cannabinoids. In: Health Canada Controlled Substances and Tobacco Directorate, editor. 2013. A comprehensive document that sets out the current understanding of cannabis pertaining to health.Google Scholar
  13. 13.
    Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708–9.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    •• Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018;1:65–72 A review that highlights the concerns about quality and safety of cannabidiol products that are currently widely publicized as therapies.CrossRefGoogle Scholar
  15. 15.
    Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: kinetics and interactions. Am J Med. 2019.Google Scholar
  16. 16.
    Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017;4(3):210–8.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Katz-Talmor D, Katz I, Porat-Katz BS, Shoenfeld Y. Cannabinoids for the treatment of rheumatic diseases—where do we stand? Nat Rev Rheumatol. 2018;14(8):488–98.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    • Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1–37 A paper that explains in detail the function of the mammalian endocannabinoid system.PubMedCrossRefGoogle Scholar
  19. 19.
    Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81(2):331–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Marquart S, Zerr P, Akhmetshina A, Palumbo K, Reich N, Tomcik M, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 2010;62(11):3467–76.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Fitzcharles MA, Ste-Marie PA, Hauser W, Clauw DJ, Jamal S, Karsh J, et al. Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. Arthritis Care Res (Hoboken). 2016;68(5):681–8.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Fitzcharles MA, Baerwald C, Ablin J, Hauser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz (Berlin, Germany). 2016;30(1):47–61.CrossRefGoogle Scholar
  23. 23.
    Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45(1):50–2.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164–73.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604–10.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial. Wien Klin Wochenschr. 2006;118(11–12):327–35.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.•
    National Academies of Sciences Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington: The National Academies Press; 2017. A comprehensive document that addresses all clinical aspects of cannabinoid use.Google Scholar
  28. 28.
    Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44–50.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Piper BJ, Beals ML, Abess AT, Nichols SD, Martin MW, Cobb CM, et al. Chronic pain patients’ perspectives of medical cannabis. Pain. 2017;158(7):1373–9.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    •• Ogourtsova T, Kalaba M, Gelinas I, Korner-Bitensky N, Ware MA. Cannabis use and driving-related performance in young recreational users: a within-subject randomized clinical trial. CMAJ Open. 2018;6(4):E453–E62 An important study that highlights the acute psychomotor impairments associated with cannabis use.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344:e536.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7(1):45–59.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293–306.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7).PubMedCentralCrossRefGoogle Scholar
  36. 36.
    Harkany T, Keimpema E, Barabas K, Mulder J. Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S84–90.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–64.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Vardaris RM, Weisz DJ, Fazel A, Rawitch AB. Chronic administration of delta-9-tetrahydrocannabinol to pregnant rats: studies of pup behavior and placental transfer. Pharmacol Biochem Behav. 1976;4(3):249–54.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Mourh J, Rowe H. Marijuana and breastfeeding: applicability of the current literature to clinical practice. Breastfeed Med. 2017;12(10):582–96.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Decuyper II, Van Gasse AL, Cop N, Sabato V, Faber MA, Mertens C, et al. Cannabis sativa allergy: looking through the fog. Allergy. 2017;72(2):201–6.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Griffith-Lendering MF, Wigman JT. Prince van Leeuwen A, Huijbregts SC, Huizink AC, Ormel J, et al. Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. Addiction. 2013;108(4):733–40.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Petker T, Owens MM, Amlung MT, Oshri A, Sweet LH, MacKillop J. Cannabis involvement and neuropsychological performance: findings from the Human Connectome Project. J Psychiatry Neurosci. 2019;44(5):1–9.CrossRefGoogle Scholar
  43. 43.••
    Hauser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018. An important European position paper on the evidence for effect of all cannabinoids in the treatment of chronic pain.Google Scholar
  44. 44.
    •• Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018;64(2):111–20 Advice to primary care physicians about prescribing medical cannabis that is evidence-based.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Department of Health England. Cannabis-based products for medicinal use. 2019 [Available from: https://www.england.nhs.uk/wp-content/uploads/2018/10/letter-guidance-on-cannabis-based-products-for-medicinal-use..pdf.
  46. 46.
    Australian_Government_Department_of_Health. Guidance for the use of medicinal cannabis in Australia 2017 [cited Australian. Available from: https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-australia-overview.
  47. 47.
    MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.CrossRefGoogle Scholar
  48. 48.
    Krcevski-Skvarc N, Wells C, Hauser W. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. Eur J Pain. 2018;22(3):440–54.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction. 2008;103(7):1100–9.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Haug NKD, Sottile J, Babson K, Vandrey R, Bonn-Miller M. Training and practices of cannabis dispensery staff. Cannabis Cannabinoid Res. 2016;1(1):244–51.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Dickson B, Mansfield C, Guiahi M, Allshouse AA, Borgelt LM, Sheeder J, et al. Recommendations from cannabis dispensaries about first-trimester cannabis use. Obstet Gynecol. 2018;131(6):1031–8.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Alan Edwards Pain Management UnitMcGill University Health CentreMontrealCanada
  2. 2.Division of RheumatologyMcGill University Health CentreQuebecCanada
  3. 3.Health Care Center for Pain Medicine and Mental Health Saarbrücken-St. JohannSaarbrückenGermany
  4. 4.Department of Psychosomatic Medicine and PsychotherapyTechnische Universität MünchenMunichGermany

Personalised recommendations